Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000185561
Ethics application status
Approved
Date submitted
21/12/2023
Date registered
27/02/2024
Date last updated
27/02/2024
Date data sharing statement initially provided
27/02/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Exploring the tolerability of nutritive and non-nutritive sweeteners in people with irritable bowel syndrome
Query!
Scientific title
Exploring the tolerability of nutritive and non-nutritive sweeteners in people with irritable bowel syndrome
Query!
Secondary ID [1]
311234
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Irritable bowel syndrome
332441
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
329132
329132
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
This study will compare for the first time, the tolerability of 5 sweeteners - erythritol, monk fruit extract, stevia, allulose and sucrose in people with IBS whose symptoms are well controlled on a low FODMAP diet.
The study will following the following order - baseline (day 1), test period 1 (Days 2-3), washout (days 4-8), test period 2 (days 9-10), washout (days 11-15), test period 3 (days 16-17), washout (18-22), test period 4 (days 23-24), washout (days 25-29), test period 5 (days 30-31).
In baseline, participants will consume their habitual, low FODMAP diet. They will also to complete a food diary, symptom questionnaire, and collect hourly breath samples from 8am to 8pm into breath collection bags.
For the 2 days of each test period, participants will consume a supplied, low FODMAP diet provided by our certified, specialty pre-made meals supplier, WeFeedYou. During each test period, they will also consume 2 test foods e.g. breakfast (smoothie), morning tea (protein ball/bar/muffin). These tests foods will be masked with 1 of the 5 test sugars (erythritol, monk fruit extract, stevia, allulose or sucrose).
Each test food will contain 1 sugar in the following amounts:
100% Sucrose - 30g
100%Erythritol - 49.4g
100%Monk fruit extract - 3.4g
100% Stevia - 0.7g
100% Allulose - 53.9g
Participants will be randomised `and blinded to the order in which they are exposed to the 5 sweeteners during the test periods. Throughout each test period, participants will also complete the food diary (to monitor compliance) and daily symptom questionnaire (to monitor tolerance). On the 2nd day of each test period, participants will also collect hourly breath samples between 8am and 8pm into breath collection bags. These breath samples will be used to assess breath hydrogen response which is a marker of fermentation in the large intestine.
In each 5 day washout period, participants will return to their habitual, low FODMAP diet.
Query!
Intervention code [1]
327690
0
Lifestyle
Query!
Comparator / control treatment
Sucrose
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
336966
0
Gastrointestinal symptoms (composite of abdominal pain, bloating/distension, satisfaction with bowel function, interference of bowel symptoms on daily life). This will be assessed using the IBS-Symptom severity score (IBS-SSS).
The IBS-SSS is a self-report questionnaire designed to assess the severity of symptoms in individuals with irritable bowel syndrome (IBS). The IBS-SSS consists of five items that assess the severity of abdominal pain, the frequency of abdominal pain, the severity of abdominal distension, dissatisfaction with bowel habits, and interference with quality of life.
The primary outcome will be the total score (0 to 500 points).
Query!
Assessment method [1]
336966
0
IBS-Symptom severity score (IBS-SSS)
Query!
Timepoint [1]
336966
0
Day 1 baseline
Day 3 intervention (test sugar 1)
Day 10 intervention (test sugar 2)
Day 17 intervention (test sugar 3)
Day 24 intervention (test sugar 4)
Day 31 intervention (test sugar 5)
Query!
Secondary outcome [1]
430275
0
Abdominal symptoms overall
Query!
Assessment method [1]
430275
0
Visual analogue scale for irritable bowel syndrome (IBS-VAS)
Query!
Timepoint [1]
430275
0
Day 1 baseline
Day 3 intervention (test sugar 1)
Day 10 intervention (test sugar 2)
Day 17 intervention (test sugar 3)
Day 24 intervention (test sugar 4)
Day 31 intervention (test sugar 5)
Query!
Secondary outcome [2]
431015
0
Abdominal pain / bloating
Query!
Assessment method [2]
431015
0
Visual analogue scale for irritable bowel syndrome (IBS-VAS)
Query!
Timepoint [2]
431015
0
Day 1 baseline
Day 3 intervention (test sugar 1)
Day 10 intervention (test sugar 2)
Day 17 intervention (test sugar 3)
Day 24 intervention (test sugar 4)
Day 31 intervention (test sugar 5)
Query!
Secondary outcome [3]
431016
0
Abdominal bloating
Query!
Assessment method [3]
431016
0
Visual analogue scale for irritable bowel syndrome (IBS-VAS)
Query!
Timepoint [3]
431016
0
Day 1 baseline
Day 3 intervention (test sugar 1)
Day 10 intervention (test sugar 2)
Day 17 intervention (test sugar 3)
Day 24 intervention (test sugar 4)
Day 31 intervention (test sugar 5)
Query!
Secondary outcome [4]
431017
0
Wind
Query!
Assessment method [4]
431017
0
Visual analogue scale for irritable bowel syndrome (IBS-VAS)
Query!
Timepoint [4]
431017
0
Day 1 baseline
Day 3 intervention (test sugar 1)
Day 10 intervention (test sugar 2)
Day 17 intervention (test sugar 3)
Day 24 intervention (test sugar 4)
Day 31 intervention (test sugar 5)
Query!
Secondary outcome [5]
431018
0
Satisfaction with stool consistency
Query!
Assessment method [5]
431018
0
Visual analogue scale for irritable bowel syndrome (IBS-VAS)
Query!
Timepoint [5]
431018
0
Day 1 baseline
Day 3 intervention (test sugar 1)
Day 10 intervention (test sugar 2)
Day 17 intervention (test sugar 3)
Day 24 intervention (test sugar 4)
Day 31 intervention (test sugar 5)
Query!
Secondary outcome [6]
431019
0
Tiredness and lethargy
Query!
Assessment method [6]
431019
0
Visual analogue scale for irritable bowel syndrome (IBS-VAS)
Query!
Timepoint [6]
431019
0
Day 1 baseline
Day 3 intervention (test sugar 1)
Day 10 intervention (test sugar 2)
Day 17 intervention (test sugar 3)
Day 24 intervention (test sugar 4)
Day 31 intervention (test sugar 5)
Query!
Secondary outcome [7]
431020
0
Nausea
Query!
Assessment method [7]
431020
0
Visual analogue scale for irritable bowel syndrome (IBS-VAS)
Query!
Timepoint [7]
431020
0
Day 1 baseline
Day 3 intervention (test sugar 1)
Day 10 intervention (test sugar 2)
Day 17 intervention (test sugar 3)
Day 24 intervention (test sugar 4)
Day 31 intervention (test sugar 5)
Query!
Eligibility
Key inclusion criteria
Irritable bowel syndrome and symptoms well controlled on a low FODMAP diet.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Age under 18 - need to be of adult consent age
- Recent gastrointestinal surgery (within last 3 months) - this would have an effect on gut symptoms
- Coeliac disease and/or other gastrointestinal disease, food allergy/intolerances, malnutrition, other dietary restrictions (e.g. vegan or vegetarian) - these conditions all require special diets and the supplied dietary intervention would potentially be contraindicated
- Pregnancy or breastfeeding - this could potentially affects gut symptoms
- Active psychological illness including eating disorders - this could affect compliance with the dietary intervention
-People living outside of metro-Melbourne
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by phone/fax/computer
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/04/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
15/07/2024
Query!
Actual
Query!
Date of last data collection
Anticipated
31/08/2024
Query!
Actual
Query!
Sample size
Target
20
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Funding & Sponsors
Funding source category [1]
315467
0
Commercial sector/Industry
Query!
Name [1]
315467
0
Modify Health
Query!
Address [1]
315467
0
190 Bluegrass Valley, Parkway, Alpharetta, Georgia 30005 , USA
Query!
Country [1]
315467
0
United States of America
Query!
Funding source category [2]
315490
0
University
Query!
Name [2]
315490
0
Monash University
Query!
Address [2]
315490
0
99 Commercial Rd, Melbourne, VIC 3004
Query!
Country [2]
315490
0
Australia
Query!
Primary sponsor type
University
Query!
Name
Monash University
Query!
Address
99 commercial Rd, Melbourne 3004
Query!
Country
Australia
Query!
Secondary sponsor category [1]
317565
0
None
Query!
Name [1]
317565
0
Query!
Address [1]
317565
0
Query!
Country [1]
317565
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
314376
0
Monas University Human Research Ethics Committee
Query!
Ethics committee address [1]
314376
0
Wellington Road Clayton Victoria 3800 Australia
Query!
Ethics committee country [1]
314376
0
Australia
Query!
Date submitted for ethics approval [1]
314376
0
16/06/2023
Query!
Approval date [1]
314376
0
13/09/2023
Query!
Ethics approval number [1]
314376
0
38778
Query!
Summary
Brief summary
little is known about the gastrointestinal effects of these sweeteners, particularly in people with irritable bowel syndrome (IBS). This study will compare for the first time, the tolerability of 5 sweeteners - erythritol, monk fruit extract, stevia, allulose and sucrose in people with IBS whose symptoms are well controlled on a low FODMAP diet. The low FODMAP diet restricts intake of six sugars - fructose, lactose, oligosaccharides (fructans and galactooligosaccharides), and sugar polyols (sorbitol, mannitol). These six sugars are well known to trigger symptoms in people with IBS, and their collective reduction via a low FODMAP diet relieves symptoms in around 3/4 people with the condition.
Query!
Trial website
Query!
Trial related presentations / publications
None
Query!
Public notes
Query!
Contacts
Principal investigator
Name
131358
0
Dr Jane Varney
Query!
Address
131358
0
Monash University, Department of Gastroenterology, Alfred Centre, 99 Commercial Rd, Melbourne VIC 3004
Query!
Country
131358
0
Australia
Query!
Phone
131358
0
+61 412944848
Query!
Fax
131358
0
Query!
Email
131358
0
[email protected]
Query!
Contact person for public queries
Name
131359
0
Jane Varney
Query!
Address
131359
0
Monash University, Department of Gastroenterology, Alfred Centre, 99 Commercial Rd, Melbourne VIC 3004
Query!
Country
131359
0
Australia
Query!
Phone
131359
0
+61 412944848
Query!
Fax
131359
0
Query!
Email
131359
0
[email protected]
Query!
Contact person for scientific queries
Name
131360
0
Jane Varney
Query!
Address
131360
0
Monash University, Department of Gastroenterology, Alfred Centre, 99 Commercial Rd, Melbourne VIC 3004
Query!
Country
131360
0
Australia
Query!
Phone
131360
0
+61 412944848
Query!
Fax
131360
0
Query!
Email
131360
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF